Efficacy and Safety of Oltipraz in the Patients With Non-alcoholic Fatty Liver Disease
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Dithiolethiones, a novel class of adenosine monophosphate-activated protein kinase (AMPK)
activators, prevent insulin resistance through AMPK-dependent p70 ribosomal S6 kinase-1
(S6K1) inhibition. And it is well known that the modulation of S6K1 by oltipraz inhibited the
development of insulin resistance and hyperglycemia through the AMPK-S6K1 pathway.Also some
research reported that LXRg (a member of the nuclear hormone receptor)-mediated increases in
SREBP-1c (the sterol regulatory element-binding protein-1c gene) promote the expression of
lipogenic genes and enhance fatty acid synthesis and oltipraz inhibits LXRg and SREBP-c.
Therefore, Oltipraz inhibits fatty acid synthesis through AMPK-S6K1 pathway and LXRg-SREBP-1c
pathway in liver.